Why We Invested in Arpeggio Bio — Making Safer And More Effective Medications

Excited to announce our investment in Arpeggio Bio, which engineers drugs to change the transcriptome, with the goal of making safer and more effective medicine. The $17M series A is being led by Builders VC and includes also existing investors Khosla Ventures, TechU, FundersClub and new investors Tencent, Formic, ATEM, BoxOne and Matt De Silva. Tau Ventures is an AI-first fund in Silicon Valley investing primarily in seed and we occasionally take earlier or later bets when we see immense promise. We are also investing in US / Canada but in exceptional cases will consider a deal outside. Arpeggio was…...